|
| Mouse IL-18BP Protein (LTP10464) |
|
| LTP10464 |
|
| 100ug |
|
|
$406 In stock |
| Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer,components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice. |
| Recombinant Mouse IL-18BP Protein is expressed from Expi293 with hFc tag at the C-terminal. It contains Thr29-Ala193. |
|
| IL-18BP |
|
| Mouse |
|
| Q9Z0M9 |
|
| Thr29-Ala193 |
|
| The protein has a predicted MW of 44.7 kDa. Due to glycosylation, the protein migrates to 60-75 kDa based on the Tris-Bis PAGE result. |
|
| 0 |
|
| C-hFc |
|
| Expi293 |
|
| > 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC |
|
| Less than 1EU per ug by the LAL method. |
|
| Lyophilized from 0.22 um filtered solution in PBS (pH 7.4). Normally 5% trehalose is added as a protectant before lyophilization. |
|
| Reconstituted protein stable at -80 C for 12 months, 4 C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
|
| Shipped at ambient temperature. |
|
| Centrifuge tubes before opening. Reconstituting to a concentration of more than 100 ug/ml is recommended. Dissolve the lyophilized protein in distilled water. |
|
|  |
